桥接治疗在大B细胞淋巴瘤CAR-T治疗中的应用进展

Progress of bridging therapy in CAR-T therapy for large B-cell lymphoma

桥接治疗是嵌合抗原受体T细胞治疗(chimeric antigen receptor T cell therapy,CAR-T)过程中的一种补充性治疗方式,其为单个核细胞采集至CAR-T细胞回输期间进行的一种抗肿瘤治疗。桥接治疗能够一定程度上延缓大B细胞淋巴瘤(large B-cell lymphoma,LBCL)进展、降低肿瘤负荷,为CAR-T细胞的顺利回输提供保障。桥接治疗的方式包括化疗、放疗、靶向治疗等。其中,桥接放疗除了保障CAR-T细胞顺利回输,还有CAR-T治疗增敏作用。本文总结了LBCL CAR-T相关桥接治疗的意义、方式及特点,旨在对桥接治疗在LBCL CAR-T治疗中的应用提供参考。

Bridging therapy serves as an adjunctive treatment during chimeric antigen receptor T cell therapy(CAR-T)and is specifically implemented after the collection of mononuclear cells but before the subsequent infusion of CAR-T cells.This approach can mitigate the progression of large B-cell lymphoma(LBCL)to a certain extent,reduce tumor burden,and facilitate the infusion of CAR-T cells.Bridging therapy includes chemotherapy,radiation therapy,and targeted therapies and ensures effective reinfusion of CAR-T cells and enhances the therapeutic efficacy of CAR-T cells.This study systematically reviews the significance,methodologies,and characteristics of CAR-T-cell-related bridging therapy for large B-cell lymphoma to provide valuable references for its clinical application.